Trial NCT Number

Trial Name

Phase

Stage

Treatment

Primary

Endpoint

Median DFS (Months)

Trial

Status

{“type”: “clinical-trial”, “attrs”: {“text”: “NCT02486718”, “term_id”: “NCT02486718”}}NCT02486718

IMpower010

Phase 3

IB-IIIA

Atezolizumab

DFS

42.3

Completed accrual

{“type”: “clinical-trial”, “attrs”: {“text”: “NCT02595944”, “term_id”: “NCT02595944”}}NCT02595944

ANVIL

Phase 3

IB-IIIA

Nivolumab

DFS and OS

Not reported

Completed Accrual

{“type”: “clinical-trial”, “attrs”: {“text”: “NCT04317534”, “term_id”: “NCT04317534”}}NCT04317534

BTCRC LUN18-153

Phase 2

I

Pembrolizumab

DFS

Not reported

Ongoing

{“type”: “clinical-trial”, “attrs”: {“text”: “NCT04585477”, “term_id”: “NCT04585477”}}NCT04585477

Not available

Phase 2

I-III

Durvalumab

Decrease in

ctDNA level

Not reported

Ongoing

{“type”: “clinical-trial”, “attrs”: {“text”: “NCT02273375”, “term_id”: “NCT02273375”}}NCT02273375

Not availabe

Phase 3

IB-IIIA

Durvalumab

DFS

Not reported

Ongoing

{“type”: “clinical-trial”, “attrs”: {“text”: “NCT02504372”, “term_id”: “NCT02504372”}}NCT02504372

PEARLS

Phase 3

IB-IIIA

Pembrolizumab

DFS

Not reported

Ongoing